HRP20140724T1 - Modulatori masnih kiselina amid hidrolaze - Google Patents
Modulatori masnih kiselina amid hidrolaze Download PDFInfo
- Publication number
- HRP20140724T1 HRP20140724T1 HRP20140724AT HRP20140724T HRP20140724T1 HR P20140724 T1 HRP20140724 T1 HR P20140724T1 HR P20140724A T HRP20140724A T HR P20140724AT HR P20140724 T HRP20140724 T HR P20140724T HR P20140724 T1 HRP20140724 T1 HR P20140724T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- disorder
- pharmaceutically acceptable
- compound
- preparation
- Prior art date
Links
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 title 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- YWGYNGCRVZLMCS-UHFFFAOYSA-N n-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide Chemical group C1=C2OC(F)(F)OC2=CC=C1CN(CC1)CCN1C(=O)NC1=CN=CC=C1Cl YWGYNGCRVZLMCS-UHFFFAOYSA-N 0.000 claims 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000018652 Closed Head injury Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021333 Ileus paralytic Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000037149 energy metabolism Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 201000007620 paralytic ileus Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
Claims (12)
1. Spoj naznačen time da je 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina (4- kloro-piridin-3-il)-amid ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski prihvatljiva sol prema zahtjevu 1, naznačena time da je spomenuta sol hidrokloridna sol 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina(4-kloro-piridin-3-il)-amida.
3. Farmaceutski prihvatljiva sol prema zahtjevu 2, naznačena time da je hidrokloridna sol bis-hidroklorid.
4. Farmaceutski pripravak, naznačen time da sadrži:
(a) terapeutski efikasnu količinu bar jednog od 4-(2,2-difluorobenzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina(4-kloro-piridin-3-il)-amid i njegova farmaceutski prihvatljiva sol; i
(b) farmaceutski prihvatljivi ekscipijent.
5. Farmaceutski pripravak prema zahtjevu 4, naznačen time da sadrži: terapeutski efikasnu količinu 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina(4-kloro-piridin-3-il)-amida ili njegove farmaceutski prihvatljive soli.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 3 ili pripravak prema zahtjevu 4 ili 5, naznačen time da je za upotrebu u terapiji.
7. Spoj ili pripravak za upotrebu prema zahtjevu 6, u postupku liječenja subjekta koji pati ili mu je dijagnosticirana bolest ili poremećaj, ili medicinsko stanje posredovano FAAH aktivnošću, naznačen time da je bolest, poremećaj ili medicinsko stanje izabrano iz grupe koju čine: anksioznost, depresija, bol, poremećaji spavanja, poremećaji ishrane, upala, poremećaji kretanja, HIV sindrom propadanja, zatvorena ozljeda glave, kap, poremećaj učenja i pamćenja, Alzheimerova bolest, epilepsija, Touretteov sindrom, Niemann-Pickova bolest, Parkinsonova bolest, Huntingtonova horeja, optički neuritis, autoimuni uveitis, odvikavanje od droga, mučnina, povraćanje, seksualna disfunkcija, posttraumatski stresni poremećaj, moždani vazospazam, glaukom, sindrom iritabilnog crijeva, upalna bolest crijeva, imunosupresija, bolest gastroezofagealnog refluksa, paralitički ileus, sekrecijska dijareja, čir želuca, reumatoidni artritis, hipertenzija, rak, hepatitis, alergijska bolest dišnih putova, autoimuni dijabetes, intraktabilni pruritis, neuritis, dijabetes, metabolički sindrom i osteoporoza.
8. Spoj ili pripravak za upotrebu prema zahtjevu 7, naznačen time da je bolest, poremećaj ili medicinsko stanje bol ili upala.
9. Spoj ili pripravak za upotrebu prema zahtjevu 7, naznačen time da je bolest, poremećaj ili medicinsko stanje anksioznost, poremećaj spavanja, poremećaj ishrane, ili poremećaj kretanja.
10. Spoj ili pripravak za upotrebu prema zahtjevu 7, naznačen time da je bolest, poremećaj ili medicinsko stanje multipla skleroza.
11. Spoj ili pripravak za upotrebu prema zahtjevu 6, naznačen time da za postupak liječenja energetskog metabolizma ili homeostaze kosti.
12. Postupak za sintezu 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina(4-kloro-piridin-3-il)-amida pomoću 2,2-difluorobenzo[1,3]dioksol-5-karbaldehida i piperazina u jednostupanjskoj reakciji hidrogenizacije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33052210P | 2010-05-03 | 2010-05-03 | |
| PCT/US2011/034755 WO2011139951A1 (en) | 2010-05-03 | 2011-05-02 | Modulators of fatty acid amide hydrolase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140724T1 true HRP20140724T1 (hr) | 2014-08-29 |
Family
ID=44080143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140724AT HRP20140724T1 (hr) | 2010-05-03 | 2014-07-28 | Modulatori masnih kiselina amid hidrolaze |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8940745B2 (hr) |
| EP (1) | EP2566861B1 (hr) |
| JP (1) | JP5841128B2 (hr) |
| KR (1) | KR101770619B1 (hr) |
| CN (1) | CN102869658B (hr) |
| AU (1) | AU2011248407B2 (hr) |
| BR (1) | BR112012028179A2 (hr) |
| CA (1) | CA2797100C (hr) |
| CL (1) | CL2012003071A1 (hr) |
| DK (1) | DK2566861T3 (hr) |
| EA (1) | EA022158B1 (hr) |
| ES (1) | ES2483242T3 (hr) |
| HR (1) | HRP20140724T1 (hr) |
| IL (1) | IL222631A (hr) |
| ME (1) | ME01912B (hr) |
| MX (1) | MX2012012759A (hr) |
| NZ (1) | NZ603175A (hr) |
| PL (1) | PL2566861T3 (hr) |
| PT (1) | PT2566861E (hr) |
| RS (1) | RS53376B (hr) |
| SG (1) | SG185411A1 (hr) |
| SI (1) | SI2566861T1 (hr) |
| SM (1) | SMT201400067B (hr) |
| UA (1) | UA108233C2 (hr) |
| WO (1) | WO2011139951A1 (hr) |
| ZA (1) | ZA201209042B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2701565C1 (ru) * | 2015-10-16 | 2019-09-30 | Импакт Биосайенсес Корп. | Способы и композиции для лечения черепно-мозговой травмы |
| WO2017066747A1 (en) * | 2015-10-16 | 2017-04-20 | Scythian Biosciences Inc. | Methods and compositions for treating gastrointestinal inflammation |
| CN111743864B (zh) * | 2020-08-05 | 2022-04-01 | 牡丹江医学院 | 一种体育外伤喷雾剂及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4810160Y1 (hr) | 1969-10-14 | 1973-03-16 | ||
| GB1292410A (en) | 1970-05-13 | 1972-10-11 | Yoshitomi Pharmaceutical | Thienobenzothiazepine derivatives |
| JPS5515456A (en) | 1978-07-19 | 1980-02-02 | Morishita Seiyaku Kk | 2-substituted-piperazinomethyl-1,4-benzodioxane |
| NZ223847A (en) | 1987-04-01 | 1989-12-21 | Janssen Pharmaceutica Nv | Substituted piperazine derivatives and pharmaceutical compositions |
| WO1993000342A1 (en) | 1991-06-21 | 1993-01-07 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
| US5612380A (en) | 1994-09-27 | 1997-03-18 | The Scripps Research Institute | Method for sleep induction |
| AU699619B2 (en) * | 1995-01-11 | 1998-12-10 | Samjin Pharmaceutical Co., Ltd. | New piperazine derivatives and methods for the preparation thereof and compositions containing the same |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| US6306959B1 (en) | 1996-05-03 | 2001-10-23 | Warner Lambert Company | Rapid purification by polymer supported quench |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| EP0968200A1 (en) * | 1997-02-24 | 2000-01-05 | ZymoGenetics, Inc. | Calcitonin mimetics |
| JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP2001522845A (ja) | 1997-11-07 | 2001-11-20 | シェーリング コーポレイション | １個の窒素原子を含有する５、６、または７員複素環式環で置換されたイミダゾイルアルキル |
| AU740588B2 (en) | 1997-11-24 | 2001-11-08 | Scripps Research Institute, The | Inhibitors of gap junction communication |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| CA2326804C (en) | 1998-03-31 | 2006-05-02 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| US6100279A (en) | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| AU1413301A (en) | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| CN1443170A (zh) | 2000-07-20 | 2003-09-17 | 神经原公司 | 辣椒素受体配体 |
| US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
| MXPA03009850A (es) | 2001-04-27 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso. |
| KR100900304B1 (ko) | 2001-06-11 | 2009-06-02 | 바이로켐 파마 인코포레이티드 | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| AU2002351200A1 (en) | 2001-12-03 | 2003-06-17 | Gpc Biotech, Inc. | Compositions and methods for inhibiting prenyltransferases |
| US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| EP1472215A4 (en) | 2002-02-08 | 2007-05-09 | Bristol Myers Squibb Co | (OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| US20040191155A1 (en) | 2003-03-25 | 2004-09-30 | Mahler Barry Asher | Thermal process for reducing the concentration of dinitrogen difluoride and dinitrogen tetrafluoride in nitrogen trifluoride |
| FR2854633B1 (fr) | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| ATE395062T1 (de) | 2003-06-10 | 2008-05-15 | Janssen Pharmaceutica Nv | Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen |
| US7262020B2 (en) | 2003-07-03 | 2007-08-28 | The Regents Of The University Of California | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol |
| FR2864080B1 (fr) * | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| CA2596393C (en) | 2004-12-30 | 2014-09-23 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other conditions |
| GB0503056D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| ITRM20060090A1 (it) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
| CA2651769C (en) | 2006-05-18 | 2013-12-17 | F. Hoffmann-La Roche Ag | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists |
| WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| DE602007011793D1 (de) | 2006-10-18 | 2011-02-17 | Pfizer Prod Inc | Biaryl-ether-harnstoffverbindungen |
| US20090062294A1 (en) | 2007-05-25 | 2009-03-05 | Richard Apodaca | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| AR068764A1 (es) | 2007-10-10 | 2009-12-02 | Takeda Pharmaceutical | N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah. |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
-
2011
- 2011-02-05 UA UAA201213737A patent/UA108233C2/ru unknown
- 2011-05-02 RS RS20140319A patent/RS53376B/en unknown
- 2011-05-02 BR BR112012028179A patent/BR112012028179A2/pt not_active Application Discontinuation
- 2011-05-02 NZ NZ603175A patent/NZ603175A/en unknown
- 2011-05-02 CN CN201180022285.3A patent/CN102869658B/zh active Active
- 2011-05-02 PT PT117191361T patent/PT2566861E/pt unknown
- 2011-05-02 AU AU2011248407A patent/AU2011248407B2/en active Active
- 2011-05-02 CA CA2797100A patent/CA2797100C/en active Active
- 2011-05-02 EP EP11719136.1A patent/EP2566861B1/en active Active
- 2011-05-02 MX MX2012012759A patent/MX2012012759A/es active IP Right Grant
- 2011-05-02 EA EA201291155A patent/EA022158B1/ru unknown
- 2011-05-02 PL PL11719136T patent/PL2566861T3/pl unknown
- 2011-05-02 US US13/695,855 patent/US8940745B2/en active Active
- 2011-05-02 ME MEP-2014-64A patent/ME01912B/me unknown
- 2011-05-02 ES ES11719136.1T patent/ES2483242T3/es active Active
- 2011-05-02 SI SI201130191T patent/SI2566861T1/sl unknown
- 2011-05-02 JP JP2013509137A patent/JP5841128B2/ja active Active
- 2011-05-02 SG SG2012081139A patent/SG185411A1/en unknown
- 2011-05-02 WO PCT/US2011/034755 patent/WO2011139951A1/en active Application Filing
- 2011-05-02 DK DK11719136.1T patent/DK2566861T3/da active
- 2011-05-02 KR KR1020127031030A patent/KR101770619B1/ko active IP Right Grant
-
2012
- 2012-10-23 IL IL222631A patent/IL222631A/en active IP Right Grant
- 2012-10-31 CL CL2012003071A patent/CL2012003071A1/es unknown
- 2012-11-29 ZA ZA2012/09042A patent/ZA201209042B/en unknown
-
2014
- 2014-06-11 SM SM201400067T patent/SMT201400067B/xx unknown
- 2014-07-28 HR HRP20140724AT patent/HRP20140724T1/hr unknown
- 2014-12-10 US US14/565,535 patent/US9688664B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11697636B2 (en) | Substituted benzamides | |
| US8008305B2 (en) | TAAR1 ligands | |
| HRP20171294T1 (hr) | Derivati fenilamid 4-(benzil)-piperazin-1-karboksilne kiseline i slični spojevi kao modulatori amidazne hidrolaze masne kiseline (faah) za liječenje tjeskobe, boli i drugih stanja | |
| HRP20140724T1 (hr) | Modulatori masnih kiselina amid hidrolaze | |
| JP2012529514A (ja) | シクロアルキルカルバメートベンズアミドアニリンｈｄａｃ阻害剤化合物 | |
| US9714239B2 (en) | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders | |
| NZ582056A (en) | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation | |
| US9359297B2 (en) | Spirolactam derivatives and uses of same | |
| US8354441B2 (en) | Oxazoline derivatives | |
| CN1432009A (zh) | 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物 | |
| HRP20151003T1 (hr) | Novi spojevi kao ligandi receptora histamina h3 | |
| RU2012122208A (ru) | 4-замещенные-2-феноксифениламиновые модуляторы дельта-опиоидных рецепторов | |
| HRP20120187T1 (hr) | Derivati 2-oksoalkil-1-piperazin-2-ona, njihovo dobivanje i njihova upotreba u terapiji | |
| KR100883937B1 (ko) | 사이토카인 억제제로서의 삼치환 우레아 | |
| CN104254521A (zh) | 反式-2-癸烯酸衍生物及含有其的药物 | |
| KR20240027769A (ko) | Mnk 억제를 나타내는 스피로사이클릭 피리딘-1,5-디온 및 이의 사용 방법 | |
| WO2023192665A2 (en) | T-type calcium channel modulators and methods of use thereof | |
| WO2023192664A2 (en) | T-type calcium channel modulators comprising a diazaspiroheptane core and methods of use thereof | |
| US8367838B2 (en) | Amines or amino alcohols as GLYT1 inhibitors |